Enveric Biosciences Reports Q1 2026 Results and Advances EB-003 Candidate
Enveric Biosciences announced its financial results and corporate updates for the first quarter of 2026, highlighting significant progress in its lead drug candidate, EB-003. The company reported that IND-enabling studies are advancing toward a planned first-in-human clinical trial. New preclinical data demonstrated that EB-003 engages dual Gq and β-arrestin signaling pathways at the 5-HT2A receptor, mechanisms associated with antidepressant and anxiolytic effects. Additionally, positive results indicated a rapid reduction in conditioned fear response in a PTSD model. On the corporate front, Enveric strengthened its intellectual property portfolio with new patent allowances for its EVM301 and EVM401 series. A notable development was the withdrawal by AbbVie Inc. of a Post-Grant Review petition previously filed by Gilgamesh Pharmaceuticals against Enveric’s patent related to the bretisilocin molecule. CEO Joseph Tucker emphasized the company's focus on non-hallucinogenic neuroplastogens and cited a supportive policy environment for mental health innovations. The company also participated in the Sachs Associates Neuroscience Innovation Forum during J.P. Morgan Week 2026.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection